FDA grants approval for Bavarian Nordic’s monkeypox vaccine

FDA grants approval for Bavarian Nordic’s monkeypox vaccine

September 25, 2019 Off By Dino Mustafić

The FDA granted the approval of Jynneos for the prevention of monkeypox disease, to Bavarian Nordic A/S, and it granted the application Priority Review, it said Tuesday in a press release.

The FDA said this is the only currently FDA-approved vaccine for the prevention of monkeypox disease.

Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research said that after the global Smallpox Eradication Program, the World Health Organization certified the eradication of naturally occurring smallpox disease in 1980. He said that routine vaccination of the American public was stopped in 1972 after the disease was eradicated in the U.S. and, as a result, a large proportion of the U.S., as well as the global population has no immunity. “Therefore, although naturally occurring smallpox disease is no longer a global threat, the intentional release of this highly contagious virus could have a devastating effect. Today’s approval reflects the U.S. government’s commitment to preparedness through support for the development of safe and effective vaccines, therapeutics, and other medical countermeasures,” he said.

The FDA said that this vaccine is also part of the Strategic National Stockpile (SNS), the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency that is severe enough to cause local supplies to be depleted. The availability of this vaccine in the SNS will help ensure that the vaccine is accessible in the U.S. if needed, the FDA said.

Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic said that Jynneos is the culmination of a fifteen-year partnership that started with a call from the NIH for a safer smallpox vaccine, successfully transitioned to BARDA and was delivered to the Strategic National Stockpile for use in an emergency.

“We are also particularly pleased with the additional indication to protect against monkeypox that creates new commercial opportunities for Jynneos,” Chaplin said.

About Smallpox

Smallpox, which is caused by the variola virus, emerged in human populations thousands of years ago and is a highly contagious and often fatal infectious disease. A person infected with smallpox typically develops a rash characterized by raised pocks on the face and body. The smallpox virus is spread through saliva and droplets from the respiratory tract or by direct or indirect contact with the virus as it is shed from skin lesions. The virus can also be spread through other body fluids and contaminated clothing or bed linen. If a person is infected with smallpox and they are in close contact with others, the virus can spread quickly.  

About Monkeypox

Monkeypox, which does not occur naturally in the U.S., is a rare disease caused by infection with monkeypox virus, which causes symptoms similar to, but milder than, smallpox. Monkeypox begins with fever, headache, muscle aches and exhaustion and can be fatal, even though it is typically milder than smallpox. It is transmitted to people from various wild animals, such as rodents and primates. In 2003, the U.S. experienced an outbreak of monkeypox, which was the first time human monkeypox was reported outside of Africa.